Publication Name	World Journal of Respirology
Manuscript ID	4316
Country	Japan

Received	2013-06-27 10:28
Peer-Review Started	2013-06-27 16:18
To Make the First Decision	2013-07-05 18:36
Return for Revision	2013-07-09 10:48
Revised	2013-07-12 18:04
Second Decision	2013-07-18 14:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-07-19 01:11
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-11-26 13:27
Publish the Manuscript Online	2013-12-03 15:44

ISSN	2218-6255 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer
Manuscript Source	Invited Manuscript
All Author List	Noriaki Sunaga, Kyoichi Kaira, Takeshi Hisada and Masanobu Yamada
Funding Agency and Grant Number
Corresponding Author	Noriaki Sunaga, MD, Department of Medicine and Molecular Science, Gunma University Graduat School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511, Japan. nsunaga@gunma-u.ac.jp
Key Words	Non-small cell lung cancer; 18F-fluorodeoxyglucose measured by positron emission tomography; Epidermal growth factor receptor mutation; Gefitinib; Erlotinib; Survival; Biomarker
Core Tip	Molecularly targeted drugs including epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which usually exhibit cytostatic antitumor activity, have emerged for the treatment of non-small cell lung cancer. The Response Evaluation Criteria in Solid Tumors is generally used to assess the therapeutic response based on the morphological changes in tumor size as evaluated by computed tomography or magnetic resonance imaging. However, such assessment may not always reflect the clinical outcome of cytostatic drugs, such as EGFR-TKIs. In this regard, 18F-fluorodeoxyglucose measured by positron emission tomography (FDG-PET) is potentially beneficial. Here we summarize the role of FDG-PET to predict the treatment efficacy in NSCLC treated with EGFR-TKIs.
Publish Date	2013-12-03 15:44
Citation	Sunaga N, Kaira K, Hisada T, Yamada M. FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer. World J Respirol 2013; 3(3): 104-109
URL	http://www.wjgnet.com/2218-6255/full/v3/i3/104.htm
DOI	http://dx.doi.org/10.5320/wjr.v3.i3.104

Full Article (PDF)	WJR-3-104.pdf
Manuscript File	4316-Review.docx
Answering Reviewers	4316-Answering reviewers.pdf
Copyright License Agreement	4316-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	4316-Language certificate.pdf
Peer-review Report	4316-Peer review(s).pdf
Scientific Editor Work List	4316-Scientific editor work list.doc